401 related articles for article (PubMed ID: 29144574)
1. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
[TBL] [Abstract][Full Text] [Related]
2. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
3. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
Perlman A; Heyman SN; Matok I; Stokar J; Muszkat M; Szalat A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1108-1113. PubMed ID: 29174031
[TBL] [Abstract][Full Text] [Related]
4. [Safety of SGLT2 inhibitors. A review of the adverse drug reactions registered in a national database].
Esteban-Jiménez O; Navarro-Pemán C; Urieta-González L
Semergen; 2018; 44(1):23-29. PubMed ID: 29183654
[TBL] [Abstract][Full Text] [Related]
5. Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.
Gudin B; Ladhari C; Robin P; Laroche ML; Babai S; Hillaire-Buys D; Faillie JL
Therapie; 2020; 75(6):641-647. PubMed ID: 32418731
[TBL] [Abstract][Full Text] [Related]
6. Thirst and drugs: A study in the World Health Organization's pharmacovigilance database.
Montastruc JL
Br J Clin Pharmacol; 2024 Jun; 90(6):1525-1528. PubMed ID: 38627211
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Bonora BM; Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
[TBL] [Abstract][Full Text] [Related]
8. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
He Z; Lam K; Zhao W; Yang S; Li Y; Mo J; Gao S; Liang D; Qiu K; Huang M; Wu J
Acta Diabetol; 2023 Mar; 60(3):401-411. PubMed ID: 36576563
[TBL] [Abstract][Full Text] [Related]
9. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
Faillie JL; Babai S; Crépin S; Bres V; Laroche ML; Le Louet H; Petit P; Montastruc JL; Hillaire-Buys D;
Acta Diabetol; 2014; 51(3):491-7. PubMed ID: 24352344
[TBL] [Abstract][Full Text] [Related]
10. Cataracts and statins. A disproportionality analysis using data from VigiBase.
Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R
Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197
[TBL] [Abstract][Full Text] [Related]
11. Statin-induced myasthenia: A disproportionality analysis of the WHO's VigiBase pharmacovigilance database.
Gras-Champel V; Batteux B; Masmoudi K; Liabeuf S
Muscle Nerve; 2019 Oct; 60(4):382-386. PubMed ID: 31298743
[TBL] [Abstract][Full Text] [Related]
12. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.
Raschi E; Piccinni C; Poluzzi E; Marchesini G; De Ponti F
Acta Diabetol; 2013 Aug; 50(4):569-77. PubMed ID: 22008948
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.
Dolladille C; Font J; Bejan-Angoulvant T; Zaman K; Sassier M; Ezine E; Stefan A; Plane AF; Legallois D; Milliez P; Parienti JJ; Alexandre J
Arch Cardiovasc Dis; 2020; 113(6-7):420-432. PubMed ID: 32418884
[TBL] [Abstract][Full Text] [Related]
14. Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®).
Batteux B; Bennis Y; Bodeau S; Masmoudi K; Hurtel-Lemaire AS; Kamel S; Gras-Champel V; Liabeuf S
Bone; 2021 Dec; 153():116137. PubMed ID: 34343739
[TBL] [Abstract][Full Text] [Related]
15. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors.
Alkabbani W; Gamble JM
Br J Clin Pharmacol; 2023 Feb; 89(2):431-439. PubMed ID: 34964156
[TBL] [Abstract][Full Text] [Related]
16. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
[TBL] [Abstract][Full Text] [Related]
17. An investigation on the association between sodium glucose co-transporter 2 inhibitors use and acute pancreatitis: A VigiBase study.
Frent I; Bucsa C; Leucuta D; Farcas A; Mogosan C
Pharmacoepidemiol Drug Saf; 2021 Oct; 30(10):1428-1440. PubMed ID: 34156119
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
19. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
[TBL] [Abstract][Full Text] [Related]
20. [Euglycemic ketoacidosis : a complication of SGLT2 inhibitors].
Mizuno A; Lolachi S; Pernet A
Rev Med Suisse; 2017 May; 13(565):1164-1167. PubMed ID: 28639760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
